Company intelligence / Profile preview
Solarea Bio
Cambridge, Massachusetts, United Statessolareabio.com ↗
- Ownership
- Private
- Employees
- ~21
- Development stage
- Commercial
01
Overview
Developing SBD111, clinically validated to slow bone loss (clinical study pending peer review & publication); launched Bondia, a novel daily medical food helping menopausal women manage bone loss
- Therapeutic areas
- OtherEndocrinologyRheumatologyImmunology
- Modalities
- Microbial-based solutionsDefined Microbial Assemblages (DMAs)Synbiotics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Solarea Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Solarea Bio.